Abstracts Archive - Page 878 of 2425 - ACR Meeting Abstracts

Abstract Number: 1794 • 2019 ACR/ARP Annual Meeting
An Evaluation of Burnout Among U.S. Rheumatology Fellows: A National Survey
Jenna McGoldrick¹, Diego Molina-Ochoa ¹, Pascale Schwab ¹, Samuel Edwards ² and Jennifer Barton ², ¹OHSU, Portland, OR, ²VA Portland Health Care System & Oregon Health & Science University, Portland, OR
Background/Purpose: Physician and trainee retention is critical given the significant projected workforce shortage of rheumatologists. While previous studies have reported significant burnout among physicians and…
Abstract Number: 1795 • 2019 ACR/ARP Annual Meeting
Education of Rheumatology Faculty: Evaluation of an Interactive Team Based Approach versus Traditional Didactic Teaching
Alysia Kwiatkowski¹, Najia Shakoor ¹, Andrew Ruthberg ¹, Joel A. Block ¹ and Sonali Khandelwal ¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: Medical schools have been moving from traditional teaching to interactive approaches. Team-based learning (TBL) is a conceptual model that focuses on learner engagement, and…
Abstract Number: 1796 • 2019 ACR/ARP Annual Meeting
Identifying Educational Themes and Knowledge Gaps Through Analysis of Electronic Consultation (eConsult) Communication Between Primary Care Physicians and Rheumatologists
Ruchi Jain¹, Anna Broder ² and Sharon Rikin ¹, ¹Montefiore Medical Center, Bronx, ²Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Despite advancements in management of rheumatologic diseases, barriers still exist for timely access to care. Electronic consultation (eConsult) use has increased in response to…
Abstract Number: 1797 • 2019 ACR/ARP Annual Meeting
Rheumatology Mechanism Madness: A Pilot Collaborative Learning Activity for Rheumatology Trainees
David Leverenz¹ and Lisa Criscione-Schreiber ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: The Community of Inquiry (CoI) is a framework to understand how a group of individuals learns together and includes concepts of social, teaching, and…
Abstract Number: 1798 • 2019 ACR/ARP Annual Meeting
Time to Bridge the Gap in Rheumatology Education: Interactive Team Based Learning Is Most Effective in Increasing Internal Medicine Residents’ Knowledge
Alysia Kwiatkowski¹, Najia Shakoor ¹, Augustine Manadan ¹, Michael Grant ¹, Joel A. Block ¹ and Sonali Khandelwal ¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: Medical education curricula have evolved to more interactive approaches. Fully interactive, team-based learning (TBL) is a flipped classroom model that has been well studied…
Abstract Number: 1799 • 2019 ACR/ARP Annual Meeting
Wellness and Resiliency Among Recent Rheumatology Fellowship Graduates: A Qualitative Study
Priyanka Iyer¹ and Bharat Kumar ², ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²University of Iowa Hospital and Clinics, Iowa City, IA
Background/Purpose: The recent ACR workforce projections suggest that there will be a significant shortage of rheumatologists by 2030. Retirement of senior physicians, an increase in…
Abstract Number: 1800 • 2019 ACR/ARP Annual Meeting
Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)
Ori Elkayam¹, Itzhak Rosner ², Devy Zisman ³, Merav Lidar ⁴, Reuven Mader ⁵, Amir Bieber ⁵, Alexandra Balbir-Gurman ⁶, Mirit Amit ⁷, Smadar Gertel ⁸ and Victoria Furer ⁹, ¹Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel, ²Bnei Tzion, Haifa, Israel, ³Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Ha emek medical center, Afula, Israel, ⁶Rambam Medical Center, Haifa, Israel, ⁷Shamir medical center, Zerifin, Israel, ⁸Tel Aviv medical center, Tel Aviv, Israel, ⁹Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: To evaluate the safety and humoral immunogenicity of a live attenuated herpes zoster (HZ) vaccine in patients with rheumatoid arthritis (RA) compared with healthy…
Abstract Number: 1801 • 2019 ACR/ARP Annual Meeting
Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Mahesh Kambhampati ², Francis Lobo ³ and Allison Petrilla ², ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The risk and cost of infection-related hospitalizations in tumor necrosis factor inhibitors (TNFi)-experienced patients with rheumatoid arthritis (RA) receiving subsequent targeted disease-modifying antirheumatic drug…
Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Urmi Khanna¹, Ariana Ellis ², AbdulAziz Galadari ³, Jeffery Hu ⁴, Josh Gallop ⁵, M. Elaine Husni ⁶ and Anthony Fernandez ⁷, ¹Department of Dermatology , Cleveland Clinic, Cleveland, OH, ²Northeast Ohio Medical University, Cleveland, OH, ³Cleveland Clinic, Abu Dhabi, Cleveland, ⁴Case Western Reserve University, Cleveland, ⁵Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ⁶Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…
Abstract Number: 1803 • 2019 ACR/ARP Annual Meeting
Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina
Rodrigo Garcia Salinas¹, Maria Alicia Lazaro ², Santiago Scarafia ³, Alejandra Cusa ², Nieves Capozzi ⁴, Luciana Casalla ⁴, Lucia Zarate ⁴, Maria de la Vega ⁵, Maria Correa ⁶, Gustavo Casado ⁷, Silvia Papasidero ⁸, Oscar Rillo ⁹, Nevil Alejandro Muñoz ¹⁰, Mariana Benegas ¹¹, Karin Kirmayr ¹², Maria Paula Girard Bosch ¹³, Maria Victoria Martire ¹⁴ and Ramiro Gomez ¹⁵, ¹Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ²IARI, Buenos Aires, ³Hospital Municipal "San Cayetano", Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Posadas, Buenos Aires, ⁵CEIM Investigaciones Medicas, Buenos Aires, Argentina, ⁶Consultorios Reumatológicos Pampa, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Hospital Militar Central, Buenos Aires, ⁸Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁹Hospital Pirovano, Buenos Aires, ¹⁰Hospital Ramos Mejia, Buenos Aires, ¹¹Sanatorio Mendez, Buenos Aires, ¹²Hospital Zonal Bariloche, Bariloche, ¹³Instituto Médico Platense, La Plata, ¹⁴Hospital San Martín. Instituto Médico Platense, La Plata, ¹⁵Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The biologics therapies in rheumatoid arthritis (RA) implies a well-known risk of infection. It is of utterly importance to count with predictive models to…
Abstract Number: 1804 • 2019 ACR/ARP Annual Meeting
Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients
Emma Stevens¹, Michael Weinblatt ¹, Elena Massarotti ², Frances Griffin ¹, Srinivas Emani ¹ and Sonali Desai ³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical S, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) and other systemic diseases (SD) are at an increased risk of developing Herpes Zoster (HZ) due to either the…
Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 1806 • 2019 ACR/ARP Annual Meeting
Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy: A Distinct Clinical Entity and Immunologic Phenotype
Uma Thanarajasingam¹, Xingxing Zhu ¹, Xian Zhou ¹, Jane Jaquith ¹, Yanfeng Li ¹ and Hu Zeng ¹, ¹Mayo Clinic, Rochester, MN
Background/Purpose: Immune checkpoint inhibitors (ICIs) are being used in the treatment of a variety of malignancies. ICIs target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell-death…
Abstract Number: 1807 • 2019 ACR/ARP Annual Meeting
Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
George J. Kahaly ¹, Saba Sile ², Elizabeth H.Z. Thompson ², Thomas Vescio ³, Renee Perdok ³, Jeffrey W. Sherman³, Terry J. Smith ⁴ and Raymond S. Douglas ⁵, ¹Johannes Gutenberg University Medical Center, Mainz, Germany, ²Horizon Therapeutics plc, Brisbane, CA, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴University of Michigan Kellogg Eye Center, Ann Arbor, MI, ⁵Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Thyroid eye disease (TED) is a debilitating autoimmune disorder characterized by inflammation and exophthalmia along with significantly altered appearance and vision changes. TED is…
Abstract Number: 1808 • 2019 ACR/ARP Annual Meeting
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation
Tawnie Braaten¹, Julie Brahmer ¹, Patrick Forde ¹, Dung Le ¹, Evan Lipson ¹, Jarushka Naidoo ¹, Megan Schollenberger ¹, Lei Zheng ¹, Michelle Jones ¹, Ami Shah ², Clifton Bingham ³ and Laura Cappelli ³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins Hospital, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The use of immune checkpoint inhibitor (ICI) therapy for malignancy is growing. Various autoimmune and inflammatory syndromes, known as immune-related adverse events (irAEs) have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].